跳至主要内容
临床试验/NCT01641081
NCT01641081已完成2 期

Phase II, Randomized, Placebo-controlled, Double-blind, Double-dummy, 5-period Complete Crossover Study of the Bronchodilator Effects of Formoterol Fumarate Inhalation Powder in Patients With Mild to Moderate Asthma.

AstraZeneca29 个研究点 分布在 1 个国家目标入组 174 人开始时间: 2012年6月最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
已完成
发起方
AstraZeneca
入组人数
174
试验地点
29
主要终点
Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) AUC0-6 After the Morning Dose (Day 14)

研究概览

简要总结

The purpose of this Phase II study is to evaluate efficacy and safety of inhaled formoterol fumarate in the Pressair DPI compared to the Foradil Aerolizer in patients with mild to moderate asthma.

This study will include a screening visit followed by a 4 month treatment period.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Experimental 1

Experimental

Formoterol Fumarate in the Pressair Pressair Dry Powder Inhaler (DPI), Low Dose

干预措施: Formoterol Fumarate in the Pressair DPI, Low Dose (Drug)

Experimental 2

Experimental

Formoterol fumarate in the Pressair Dry Powder Inhaler (DPI), High Dose

干预措施: Formoterol Fumarate in the Pressair DPI, High Dose (Drug)

Active Comparator 1

Active Comparator

Foradil Aerolizer, Low Dose

干预措施: Foradil Aerolizer, Low Dose (Drug)

Active Comparator 2

Active Comparator

Foradil Aerolizer, High Dose

干预措施: Foradil Aerolizer, High Dose (Drug)

Placebo

Placebo Comparator

Dose matched placebo

干预措施: Placebo (Drug)

结局指标

主要结局

Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) AUC0-6 After the Morning Dose (Day 14)

时间窗: Baseline and up to 6 hrs post-dose (±15 min) on Day 14 of treatment

AUC0-6 is area under the curve from time 0 to 6 hours Serial spirometry was performed at -60 min predose, at 5 (+5) and 30 (±5) min post-dose, and at 1, 2, 3, 4, and 6 hrs post-dose (±15 min) Change from baseline was baseline of each treatment period The normalized FEV1 AUC0-6 was calculated by means of the trapezoidal method, dividing the area under the curve by the corresponding time intervals

次要结局

  • Change From Baseline in Normalized FEV1 AUC0-6 After the Morning Dose (Day 1)(Baseline and up to 6 hrs post-dose (±15 min) on Day 1 of treatment)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (29)

Loading locations...

相似试验